The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5, as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Members of the U.S. military who were vaccinated against Covid-19 showed higher-than-expected rates of heart inflammation, although the condition was still extremely rare, according to a study released on June 29.

Israel’s Health Ministry found the small number of heart inflammation cases observed mainly in young men who received Pfizer’s Covid-19 vaccine in Israel were likely linked to the company’s vaccination.

The U.S. Food and Drug Administration released a briefing document on May 4 citing concerns regarding clinical data for ChemoCentryx’s investigational rare autoimmune disease therapy avacopan. ChemoCentryx is seeking approval from the FDA for the drug as a therapeutic agent for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

The U.S. Centers for Disease Control and Prevention (CDC) has not found a link between heart inflammation and Covid-19 vaccines, the agency’s Director Rochelle Walensky said on April 27.

Blocking TNF production could offer a more effective solution for the treatment of COVID-19.

Researchers at Johns Hopkins Medicine identified a protein – known as factor D – that appears essential to the inflammatory process of SARS-CoV-2, the virus that causes Covid-19.

In a Phase III study, the biologic Dupixent met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.

Topline results from a 28-week Phase IIb trial show that lenabasum, a novel oral small molecule developed by Massachusetts-based Corbus Pharmaceuticals, did not reduce the rate of new pulmonary exacerbations compared with placebo in patients with cystic fibrosis (CF).

Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.